Global Multiple Sclerosis Drugs Market Size, Share, Forecast Report, 2020-2027

The global Multiple Sclerosis Drugs market garnered revenue around USD 25.01 Billion in 2019 and projected to reach USD 40.65 Billion in 2027, with at a compound annual growth rate (CAGR) 7.2% throughout the estimate period from 2020 to 2027.         

Multiple sclerosis is a central nervous system disorder. It is a potentially disabling disease of the spinal cord and brain. In multiple sclerosis, the immune system attacks the myelin (protective sheath) that shields nerve fibers, which causes communication issues between the brain and the rest of the body. Multiple sclerosis can cause permanent deterioration or damage to the nerves. The cause of multiple sclerosis is still unknown. Researchers believe that genetic and environmental factors contribute to the risk of developing multiple sclerosis.

Rise in prevalence and incidence of multiple sclerosis, rapid increase in the geriatric population leading a surge in cases of multiple sclerosis, and increase in awareness about multiple sclerosis are the major factors fueling the growth of the multiple sclerosis drugs market.

This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.

The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Multiple Sclerosis Drugs market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Multiple Sclerosis Drugs market growth.

The global Multiple Sclerosis Drugs market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.

Major manufacturers analysed under this study comprises:

the multiple sclerosis drugs market. Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), and AbbVie, Inc.

This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:

Global Multiple Sclerosis Drugs Market: Segmentation

  • Multiple Sclerosis Drugs Market, by Drug Class
    • Interferon Beta
    • Sphingosine 1 Phosphate Receptor Modulators
    • Mixed Polymers
    • NF-κB Inhibitor
    • Pyrimidine Synthesis Inhibitor
    • Monoclonal Antibodies
    • Corticosteroids
    • Adrenocorticotropic Hormone
    • Others
  • Multiple Sclerosis Drugs Market, by Disease Type
    • Relapsing-remitting MS (RRMS)
    • Primary-progressive MS (PPMS)
    • Secondary-progressive MS (SPMS)
    • Progressive-relapsing MS (PRMS)
  • Multiple Sclerosis Drugs Market, by Route of Administration
    • Parenteral
    • Oral
  • Multiple Sclerosis Drugs Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies & Drug Stores
    • Online Pharmacies

Regional Analysis and Forecast

Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Rest of EU
  • Asia Pacific
    • China
    • India
    • Japan
    • Southeast Asia
    • Rest of APAC
  • Central & South America
    • Brazil
    • Argentina
    • Rest of Central & South America
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • Rest of MEA